{"id":390707,"date":"2018-04-10T00:00:00","date_gmt":"2018-04-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0005-2018-biopharma-psoriasis-unmet-need-us-eu-2018\/"},"modified":"2026-04-21T05:27:18","modified_gmt":"2026-04-21T05:27:18","slug":"unneim0005-2018-biopharma-psoriasis-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0005-2018-biopharma-psoriasis-unmet-need-us-eu-2018\/","title":{"rendered":"Psoriasis | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p>IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-\u03b1 inhibitors and the IL-12\/23 inhibitor Stelara. Although IL-17 inhibitors are starting to be prescribed in earlier lines of therapy, the biologics market is still dominated by TNF-\u03b1 inhibitors and Stelara. Nonetheless, emerging therapies may find opportunities to address the unmet needs in the moderate to severe psoriasis market identified in this report.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for psoriasis?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new moderate to severe psoriasis drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, United Kingdom, France, Germany.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 60 U.S. and 30 European dermatologists fielded in January and February 2018.<\/p>\n<p><strong>Key companies:\u00a0<\/strong>AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis.<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Tremfya.<\/p>\n","protected":false},"template":"","class_list":["post-390707","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390707\/revisions"}],"predecessor-version":[{"id":393831,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390707\/revisions\/393831"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}